For digital healthcare companies, demonstrating sustainable growth is often more important than simply generating an initial surge in revenue. For MedPal AI plc (LSE:MPAL), August provided a significant indication of what could be possible as its growing healthcare platform begins to scale.
Following the launch of marketing for its New Health private healthcare proposition in July, MedPal AI saw its annualised revenue run rate rise dramatically from approximately £8.6 million to around £28 million in August.
Importantly, the growth was achieved through organic trading, rather than acquisition-led expansion, highlighting the traction the company’s proposition has achieved with patients.
At the heart of the acceleration was New Health, which attracted more than 16,000 purchasing customers within weeks, significantly exceeding the company’s initial expectations.
According to CEO Jason Drummond, the catalyst was relatively straightforward: New Health’s proposition of fair pricing, ongoing clinical support and technology designed to reduce the cost of healthcare delivery appears to have strongly resonated with consumers.
The scale and speed of that response could prove particularly significant because the customers being acquired are not simply one-off transactions. MedPal AI’s strategy is increasingly centred on building recurring relationships with patients across multiple healthcare services.
A rapid transition to recurring revenues
The August numbers represent an important milestone in a remarkable period of development for MedPal AI.
The company has moved from effectively zero revenue in October 2025 to approximately £28 million of annualised revenue in just ten months.
While management is rightly cautious about extrapolating a single month’s performance into a forecast, the underlying structure of the business provides an important reason for optimism.
Multiple parts of the platform generate recurring revenue, including monthly private healthcare treatment plans, NHS prescriptions and software subscriptions.
That creates a fundamentally different growth dynamic from a business dependent on continually finding new customers simply to replace lost revenue.
As Drummond explained, each month begins with the previous month’s customer base, providing a growing foundation from which the company can build.
And importantly, MedPal AI says its existing infrastructure has the capacity to support volumes many times higher than those currently being processed.
New Health opens the door to a much larger opportunity
The rapid adoption of New Health also gives MedPal AI exposure to a rapidly expanding private healthcare market.
Demand for GLP-1 weight-management treatments continues to develop, while the recent availability of oral GLP-1 treatment in the UK creates another potential avenue for patient growth.
MedPal AI’s positioning is built around providing consumers with accessible pricing while maintaining clinical support and technology-enabled healthcare delivery.
That combination could become increasingly attractive as consumers look for alternatives that deliver both value and quality.
For MedPal AI, however, the opportunity extends beyond simply acquiring private healthcare patients.
Every New Health customer represents a potential long-term relationship with the wider MedPal platform.
One patient, multiple revenue opportunities
This is arguably one of the most compelling elements of the company’s strategy.
MedPal AI is developing operations across private healthcare, NHS prescription dispensing, care home medication and digital healthcare software, with the different businesses increasingly designed to work together.
The NHS prescription market alone represents a substantial opportunity, with the NHS spending close to £1 billion a month on prescription medicines, according to management.
MedPal’s dispensing infrastructure, including its large-scale robotic dispensing operation, provides the company with the capacity to participate in this market as volumes grow.
Meanwhile, its EMRX care home software provides another route into the medication-management market, while Juno is positioned as a technology layer capable of supporting patient engagement across the wider ecosystem.
The result is a potentially powerful model: acquire a customer once, then serve that customer through multiple parts of the healthcare platform.
For investors, that creates the possibility of increasing customer lifetime value without requiring the company to repeatedly incur the full cost of acquiring the same patient.
Infrastructure already in place
Another important factor behind MedPal AI’s growth strategy is that the company has already invested in the infrastructure required to support significantly greater volumes.
That means the next stage of growth does not necessarily require a proportional increase in physical infrastructure.
As additional patients and prescriptions move through the platform, incremental revenue can potentially flow through an established operational base, providing an opportunity for margin expansion as scale increases.
The economics of the group’s software operations are also noteworthy. Management highlighted EMRX’s 82% gross margin, demonstrating the potential value of combining high-margin software revenues with the group’s healthcare and dispensing operations.
This combination of infrastructure and recurring software revenue could become increasingly important as MedPal AI scales.
Three major markets, one connected platform
MedPal AI is effectively operating across three substantial healthcare markets: NHS prescription dispensing, care home medication management and private healthcare.
What makes the strategy particularly interesting is the connectivity between them.
A New Health patient who initially joins the platform for private treatment could potentially become an NHS prescription customer.
A care home using EMRX could become a customer of the group’s pharmacy supply operation.
And Juno can sit across the ecosystem, helping maintain patient engagement and creating another technology-enabled relationship with the end user.
This creates the potential for a flywheel effect, where growth in one part of the business generates opportunities for another.
Rather than operating as a collection of disconnected healthcare businesses, MedPal AI is attempting to build an integrated digital healthcare operating system.
From proof of concept to the next stage of growth
The most striking aspect of MedPal AI’s recent progress may ultimately be the speed at which the business has reached its current position.
Going from zero in October 2025 to an annualised revenue run rate of approximately £28 million by August 2026 represents a dramatic transformation in less than a year.
The August acceleration provides further evidence that the company’s strategy can translate investment in technology, infrastructure and patient acquisition into rapidly increasing revenues.
There will inevitably be questions around how the exceptional August growth develops over subsequent months, and management itself has stressed that one month’s performance should not be treated as a forecast.
However, the underlying ingredients are increasingly in place: a rapidly growing customer base, recurring revenue streams, significant addressable markets, established infrastructure and the potential to generate multiple revenue streams from individual customers.
For investors watching the evolution of the digital healthcare sector, MedPal AI is therefore becoming an increasingly interesting company to follow.
The transformation is already substantial.
But with New Health still in its early stages, the wider platform continuing to develop and significant spare capacity across the group’s infrastructure, Jason Drummond’s assessment that “we’re at the starting line, definitely not the finish” could prove to be one of the most important takeaways from the latest update.
